溴隐亭(bromocriptine,BRC)作为治疗泌乳素腺瘤的一线药物,不仅能有效控制肿瘤体积,同时可使血清泌乳素(prolactin,PRL)下降至正常水平[1,2]。但临床上仍有10%~20%泌乳素腺瘤患者在长时间溴隐亭治疗过程中血清PRL水平未能恢复正常,甚至出现肿瘤持续增长的情况,即耐药现象[3,4] Bromocriptine (BRC), as a first-line drug for the treatment of prolactinomas, can not only effectively control the tumor volume, but also reduce the serum prolactin (PRL) level to a normal level [1,2]. However, 10% to 20% of patients with prolactinomas are still clinically unable to return to normal levels of PRL during the course of long-term treatment with bromocriptine, and even cases of persistent tumor growth, that is, drug resistance [3,4]